Author: Ravi Shankar

• Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiation
• Strengthened financial position through an oversubscribed ~€86 million global follow-on offering completed in May 2026, extending cash runway into 2029
• Acceptable safety profile and promising initial efficacy responses observed in Johnson & Johnson-led Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) in Stage 3 unresectable NSCLC
• U.S. FDA clearance for protocol amendment to the Johnson & Johnson-led Phase 3 NANORAY-312 study evaluating JNJ-1900 (NBTXR3) in locally advanced platinum ineligible head and neck cancer
• €110.9 million in cash and cash equivalents as of June 30, 2026

PARIS and CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today provided an update on operational progress and reported financial results for the first six months of 2026.

“Our progress in the first half of 2026 continues to support our belief that a physics-based approach to the design and development of nanotherapeutics has the potential to revolutionize treatment possibilities for millions of patients around the world,” said Laurent Levy, Chief Executive Officer and Chairman of the Executive Board at Nanobiotix. “The JNJ-1900 (NBTXR3) clinical development program continued to produce encouraging data across multiple indications, and adjustments to the Phase 3 NANORAY-312 protocol streamlined the study toward the final analysis. Longstanding shareholders and new investors alike expressed confidence in our vision through our recent capital raise. We enter the second half strategically, operationally, and financially equipped to continue supporting Nanoradioenhancer JNJ-1900 (NBTXR3) and advancing next wave nanotherapeutic platforms such as Nanoprimer.”

Operational Highlights

• New data from Phase 1 NSCLC study sponsored by The University of Texas MD Anderson Cancer Center (“UT MD Anderson”) presented at 2026 WCLC Meeting:
  • At a median follow-up of 12 months, the one-year locoregional control rate was 79%. One-year local progression-free survival (“LPFS”) was 61%, and one-year overall survival (“OS”) was 70% in evaluable patients.
  • Investigators concluded that JNJ-1900 (NBTXR3) may permit clinically meaningful local control using a substantially lower re-irradiation dose.
  • All 24 patients completed treatment with JNJ-1900 (NBTXR3) plus re-irradiation with no dose-limiting toxicities
  • No Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3) or to the injection procedure were reported
  • The recommended Phase 2 dose was established at 33% of gross tumor volume

• Included in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe’s leading and high-growth technology companies among international investors.
• Closed a global follow-on offering with underwriters’ over-allotment option fully exercised, bringing total gross proceeds to approximately €86 million that will support continued develop of Nanobiotix’s broader therapeutic platforms
• Part 1 data from Johnson & Johnson (“J&J”)-led Phase 2 JNJ-1900 (NBTXR3) Study in Unresectable Stage 3 NSCLC (CONVERGE) presented at ELCC 2026 and updated at ESTRO 2026
  • Initial investigator-reported efficacy responses observed in 7 patients following the full treatment regimen of JNJ-1900 (NBTXR3) given prior to concurrent chemoradiotherapy, and consolidation with durvalumab) showed:
    • Overall response rate (“ORR”) = 85.7% (6/7 patients) reported at ESTRO 2026
      • In the same cohort of 7 patients, ORR observed at earlier time point and reported at ELCC 2026 was 71.4% (5/7 patients)
    • Complete response rate (“CRR”) = 57.1% (4/7 patients) reported at ESTRO 2026
      • With the current standard of care, concurrent chemoradiation therapy (cCRT) + durvalumab, depth of response remains limited in Stage 3 unresectable NSCLC with very low rates of complete response (~15%)¹
    • Deepening response over time suggests potential for long-term durability
    • The procedure demonstrated an acceptable safety profile without serious treatment-emergent adverse events (TEAEs)
  • Early results suggest that intratumoral/intranodal injection of JNJ-1900 (NBTXR3) is feasible and can be performed safely in patients with stage III unresectable NSCLC
• Protocol amendment to J&J-led global Phase 3 JNJ-1900 (NBTXR3) study in Cisplatin-ineligible Head and Neck Cancer (NANORAY-312)
  • Eliminated previously planned interim analysis eliminated and modified the final analysis to include fewer events than originally planned to be conducted sooner
• New preclinical data presented at 2026 AACR Meeting
  • Pre-treatment with Nanoprimer followed by administration of LNP-delivered recombinant DNA (“LNP-DNA”) designed for anti-tumor immunotherapy showed increased systemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING related inflammation compared to LNP-DNA administered without the Nanoprimer

Half Year 2026 Financial Results

Revenue and Other Income: Revenue and other income amounted to €5.6 million for the six months ended June 30, 2026, as compared to €26.6 million for the same period in 2025. This variance is mainly due to a significant one-off non-cash revenue positive impact amounting to €21.2 million recorded over the first half of 2025 in accordance with IFRS15 revenue recognition accounting principles, further to the transfer of NANORAY-312 study sponsorship to Johnson & Johnson. In addition, Revenue and Other Income for the six months ended June 30, 2026 also included €3.1 million of clinical product supply sales to Johnson & Johnson (as compared to €3.4 million for the same period in 2025) and research tax credit income amounting to €1.9 million (as compared to €1.6 million for the same period in 2025).

Research and Development (“R&D”) Expenses: R&D expenses consist primarily of preclinical, clinical and manufacturing expenses including employee-related payroll costs and shared-based payment charges related to the development of JNJ-1900 (NBTXR3) and of new platforms. These R&D expenses for the six months ending June 30 2026, were €12.7 million as compared to €14.5 million for the same period in 2025. The €1.8 million favorable variance was primarily driven by lower clinical development and JNJ-1900 (NBTXR3) production activities in NANORAY-312 study further to the transfer of sponsorship to Johnson & Johnson, and by less patient recruitment on the studies Study 1100 and lower UT MD Anderson studies expense during first half of 2026 as compared to the same period in 2025.

Selling, General and Administrative (“SG&A”) Expenses: SG&A expenses consist primarily of administrative employee-related payroll costs, share-based payment charges, insurance, IP, legal, audit and other professional fees. Total SG&A expenses for the six months ending June 30, 2026, were €10.8 million, as compared to €11.3 million for the same period in 2025. The €0.5 million favorable variance is mainly due to the impact of social charges related to stock-option plan and severance expenses occurred over the first half of 2025.

Net loss: Net loss attributable to common shareholders for the six months ending June 30, 2026, was €34.3 million, or a €0.70 basic loss per share. This compares to a net loss attributable to common shareholders of €5.4 million, or €0.11 basic loss per share, for the same period in 2025.

Cash and Cash Equivalents: Cash and Cash Equivalents as of June 30, 2026 were €110.9 million, compared to €52.8 million as of December 31, 2025.

Financial Guidance: Based on the current operating plan and financial projections, the Company anticipates that the cash and cash equivalents of €110.9 million as of June 30, 2026 will fund its operations into 2029.

Availability of the Half Year 2026 Financial Reports

The 2026 half-year financial report has been filed with the French financial market authority (Autorité des marchés financiers) and with the U.S. Securities and Exchange Commission on September 24, 2026. It is available to the public on the Company’s website, www.nanobiotix.com.

About JNJ-1900 (NBTXR3)

JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy. The product candidate’s mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when in the presence of radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Proof-of-concept was demonstrated in a randomized Phase 2/3 soft tissue sarcoma study sponsored by Nanobiotix in 2018.

JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations.

In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy.

In 2023, Nanobiotix announced a license agreement for the global development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company. Studies being led by Johnson & Johnson include NANORAY-312 (NCT04892173), a global, randomized Phase 3 study in platinum-based chemotherapy-ineligible, locally advanced head and neck squamous cell cancers; LUMIRAY (NCT07219212), a global, phase 1b, open-label study in locally advanced head and neck squamous cell cancers; and CONVERGE (NCT06667908), a phase 2, randomized, open-label, active-controlled study in locally advanced and unresectable Stage III non-small cell lung cancer (NSCLC).

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on March 31, 2026 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2025 universal registration document filed with the AMF on March 31, 2026 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2026, which are available on the SEC’s website at www.sec.gov and on the AMF’s website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 joanne.choi@nanobiotix.com Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 6 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

¹Antonia SJ, et al. N Engl J Med. 2017.

Attachment

• 2026-09-24 — NBTX — 1H26 Financial Results — FINAL

• Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiation
• Strengthened financial position through an oversubscribed ~€86 million global follow-on offering completed in May 2026, extending cash runway into 2029
• Acceptable safety profile and promising initial efficacy responses observed in Johnson & Johnson-led Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) in Stage 3 unresectable NSCLC
• U.S. FDA clearance for protocol amendment to the Johnson & Johnson-led Phase 3 NANORAY-312 study evaluating JNJ-1900 (NBTXR3) in locally advanced platinum ineligible head and neck cancer
• €110.9 million in cash and cash equivalents as of June 30, 2026

PARIS and CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today provided an update on operational progress and reported financial results for the first six months of 2026.

“Our progress in the first half of 2026 continues to support our belief that a physics-based approach to the design and development of nanotherapeutics has the potential to revolutionize treatment possibilities for millions of patients around the world,” said Laurent Levy, Chief Executive Officer and Chairman of the Executive Board at Nanobiotix. “The JNJ-1900 (NBTXR3) clinical development program continued to produce encouraging data across multiple indications, and adjustments to the Phase 3 NANORAY-312 protocol streamlined the study toward the final analysis. Longstanding shareholders and new investors alike expressed confidence in our vision through our recent capital raise. We enter the second half strategically, operationally, and financially equipped to continue supporting Nanoradioenhancer JNJ-1900 (NBTXR3) and advancing next wave nanotherapeutic platforms such as Nanoprimer.”

Operational Highlights

• New data from Phase 1 NSCLC study sponsored by The University of Texas MD Anderson Cancer Center (“UT MD Anderson”) presented at 2026 WCLC Meeting:
  • At a median follow-up of 12 months, the one-year locoregional control rate was 79%. One-year local progression-free survival (“LPFS”) was 61%, and one-year overall survival (“OS”) was 70% in evaluable patients.
  • Investigators concluded that JNJ-1900 (NBTXR3) may permit clinically meaningful local control using a substantially lower re-irradiation dose.
  • All 24 patients completed treatment with JNJ-1900 (NBTXR3) plus re-irradiation with no dose-limiting toxicities
  • No Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3) or to the injection procedure were reported
  • The recommended Phase 2 dose was established at 33% of gross tumor volume

• Included in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe’s leading and high-growth technology companies among international investors.
• Closed a global follow-on offering with underwriters’ over-allotment option fully exercised, bringing total gross proceeds to approximately €86 million that will support continued develop of Nanobiotix’s broader therapeutic platforms
• Part 1 data from Johnson & Johnson (“J&J”)-led Phase 2 JNJ-1900 (NBTXR3) Study in Unresectable Stage 3 NSCLC (CONVERGE) presented at ELCC 2026 and updated at ESTRO 2026
  • Initial investigator-reported efficacy responses observed in 7 patients following the full treatment regimen of JNJ-1900 (NBTXR3) given prior to concurrent chemoradiotherapy, and consolidation with durvalumab) showed:
    • Overall response rate (“ORR”) = 85.7% (6/7 patients) reported at ESTRO 2026
      • In the same cohort of 7 patients, ORR observed at earlier time point and reported at ELCC 2026 was 71.4% (5/7 patients)
    • Complete response rate (“CRR”) = 57.1% (4/7 patients) reported at ESTRO 2026
      • With the current standard of care, concurrent chemoradiation therapy (cCRT) + durvalumab, depth of response remains limited in Stage 3 unresectable NSCLC with very low rates of complete response (~15%)¹
    • Deepening response over time suggests potential for long-term durability
    • The procedure demonstrated an acceptable safety profile without serious treatment-emergent adverse events (TEAEs)
  • Early results suggest that intratumoral/intranodal injection of JNJ-1900 (NBTXR3) is feasible and can be performed safely in patients with stage III unresectable NSCLC
• Protocol amendment to J&J-led global Phase 3 JNJ-1900 (NBTXR3) study in Cisplatin-ineligible Head and Neck Cancer (NANORAY-312)
  • Eliminated previously planned interim analysis eliminated and modified the final analysis to include fewer events than originally planned to be conducted sooner
• New preclinical data presented at 2026 AACR Meeting
  • Pre-treatment with Nanoprimer followed by administration of LNP-delivered recombinant DNA (“LNP-DNA”) designed for anti-tumor immunotherapy showed increased systemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING related inflammation compared to LNP-DNA administered without the Nanoprimer

Half Year 2026 Financial Results

Revenue and Other Income: Revenue and other income amounted to €5.6 million for the six months ended June 30, 2026, as compared to €26.6 million for the same period in 2025. This variance is mainly due to a significant one-off non-cash revenue positive impact amounting to €21.2 million recorded over the first half of 2025 in accordance with IFRS15 revenue recognition accounting principles, further to the transfer of NANORAY-312 study sponsorship to Johnson & Johnson. In addition, Revenue and Other Income for the six months ended June 30, 2026 also included €3.1 million of clinical product supply sales to Johnson & Johnson (as compared to €3.4 million for the same period in 2025) and research tax credit income amounting to €1.9 million (as compared to €1.6 million for the same period in 2025).

Research and Development (“R&D”) Expenses: R&D expenses consist primarily of preclinical, clinical and manufacturing expenses including employee-related payroll costs and shared-based payment charges related to the development of JNJ-1900 (NBTXR3) and of new platforms. These R&D expenses for the six months ending June 30 2026, were €12.7 million as compared to €14.5 million for the same period in 2025. The €1.8 million favorable variance was primarily driven by lower clinical development and JNJ-1900 (NBTXR3) production activities in NANORAY-312 study further to the transfer of sponsorship to Johnson & Johnson, and by less patient recruitment on the studies Study 1100 and lower UT MD Anderson studies expense during first half of 2026 as compared to the same period in 2025.

Selling, General and Administrative (“SG&A”) Expenses: SG&A expenses consist primarily of administrative employee-related payroll costs, share-based payment charges, insurance, IP, legal, audit and other professional fees. Total SG&A expenses for the six months ending June 30, 2026, were €10.8 million, as compared to €11.3 million for the same period in 2025. The €0.5 million favorable variance is mainly due to the impact of social charges related to stock-option plan and severance expenses occurred over the first half of 2025.

Net loss: Net loss attributable to common shareholders for the six months ending June 30, 2026, was €34.3 million, or a €0.70 basic loss per share. This compares to a net loss attributable to common shareholders of €5.4 million, or €0.11 basic loss per share, for the same period in 2025.

Cash and Cash Equivalents: Cash and Cash Equivalents as of June 30, 2026 were €110.9 million, compared to €52.8 million as of December 31, 2025.

Financial Guidance: Based on the current operating plan and financial projections, the Company anticipates that the cash and cash equivalents of €110.9 million as of June 30, 2026 will fund its operations into 2029.

Availability of the Half Year 2026 Financial Reports

The 2026 half-year financial report has been filed with the French financial market authority (Autorité des marchés financiers) and with the U.S. Securities and Exchange Commission on September 24, 2026. It is available to the public on the Company’s website, www.nanobiotix.com.

About JNJ-1900 (NBTXR3)

JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy. The product candidate’s mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when in the presence of radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Proof-of-concept was demonstrated in a randomized Phase 2/3 soft tissue sarcoma study sponsored by Nanobiotix in 2018.

JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations.

In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy.

In 2023, Nanobiotix announced a license agreement for the global development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company. Studies being led by Johnson & Johnson include NANORAY-312 (NCT04892173), a global, randomized Phase 3 study in platinum-based chemotherapy-ineligible, locally advanced head and neck squamous cell cancers; LUMIRAY (NCT07219212), a global, phase 1b, open-label study in locally advanced head and neck squamous cell cancers; and CONVERGE (NCT06667908), a phase 2, randomized, open-label, active-controlled study in locally advanced and unresectable Stage III non-small cell lung cancer (NSCLC).

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on March 31, 2026 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2025 universal registration document filed with the AMF on March 31, 2026 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2026, which are available on the SEC’s website at www.sec.gov and on the AMF’s website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 joanne.choi@nanobiotix.com Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 6 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

¹Antonia SJ, et al. N Engl J Med. 2017.

Attachment

• 2026-09-24 — NBTX — 1H26 Financial Results — FINAL

ISSAQUAH, Wash., Sept. 24, 2026 (GLOBE NEWSWIRE) — Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today announced its operating results for the 16-week fourth quarter and the 52-week fiscal year ended August 30, 2026.

Net sales for the quarter increased 11.2 percent, to $93.9 billion, from $84.4 billion last year. Net sales for the fiscal year increased 10.1 percent, to $297.2 billion, from $269.9 billion last year.

Comparable sales for the fourth quarter and fiscal year were as follows:

	16 Weeks		16 Weeks		52 Weeks		52 Weeks
			Adjusted*				Adjusted*
U.S.	10.7%		7.2%		8.2%		6.6%
Canada	5.0%		4.6%		7.8%		6.7%
Other International	7.0%		6.2%		9.8%		6.5%
Total Company	9.4%		6.7%		8.4%		6.6%
Digitally-Enabled	19.5%		19.8%		20.9%		20.7%

_{*Excluding the impacts from changes in gasoline prices and foreign exchange.}

Net income for the fourth quarter was $2.998 billion, $6.75 per diluted share, compared to $2.610 billion, $5.87 per diluted share, last year. This year’s fourth quarter was positively impacted by a non-recurring benefit of $0.15 per diluted share from IEEPA tariff refunds received in the quarter, less partial reinvestment of those refunds in increased member values. Net income for the fiscal year was $9.226 billion, $20.76 per diluted share, compared to $8.099 billion, $18.21 per diluted share, last year.

Costco currently operates 939 warehouses, including 647 in the United States and Puerto Rico, 115 in Canada, 43 in Mexico, 37 in Japan, 29 in the United Kingdom, 20 in Korea, 15 in Australia, 14 in Taiwan, seven in China, five in Spain, three in France, two in Sweden, and one each in Iceland, and New Zealand. Costco also operates e-commerce sites in the U.S., Canada, the U.K., Mexico, Korea, Taiwan, Japan, Australia, and China.

A conference call to discuss these results is scheduled for 2:00 p.m. (PT) today, September 24, 2026, and will be available via a webcast on investor.costco.com (click “Events & Presentations”).

Certain statements contained in this document constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For these purposes, forward-looking statements are statements that address activities, events, conditions or developments that the Company expects or anticipates may occur in the future. In some cases forward-looking statements can be identified because they contain words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms. Such forward-looking statements involve risks and uncertainties that may cause actual events, results or performance to differ materially from those indicated by such statements. These risks and uncertainties include, but are not limited to, domestic and international economic conditions, including exchange rates, inflation or deflation, the effects of competition and regulation, uncertainties in the financial markets, consumer and small business spending patterns and debt levels, breaches of security or privacy of member or business information, conditions affecting the acquisition, development, ownership or use of real estate, capital spending, actions of vendors, rising costs associated with employees (generally including health-care costs and wages), workforce interruptions, energy and certain commodities, geopolitical conditions (including tariffs and global conflicts), the ability to maintain effective internal control over financial reporting, regulatory and other impacts related to environmental and social matters, public-health related factors, and other risks identified from time to time in the Company’s public statements and reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company does not undertake to update these statements, except as required by law. Comparable sales and comparable sales excluding impacts from changes in gasoline prices and foreign exchange are intended as supplemental information and are not a substitute for net sales presented in accordance with U.S. GAAP.

CONTACTS:	Costco Wholesale Corporation
	Josh Dahmen, 425/313-8254
	Andrew Yoon, 425/313-6305
	Bryan Starnes, 425/427-7403

COST-Earn

COSTCO WHOLESALE CORPORATION CONSOLIDATED STATEMENTS OF INCOME (dollars in millions, except per share data) (unaudited)
	16 Weeks Ended								52 Weeks Ended
	August 30, 2026				August 31, 2025				August 30, 2026				August 31, 2025
REVENUE
Net sales	$	93,873			$	84,432			$	297,247			$	269,912
Membership fees		1,850				1,724				5,907				5,323
Total revenue		95,723				86,156				303,154				275,235
OPERATING EXPENSES
Merchandise costs		83,531				75,037				264,279				239,886
Selling, general and administrative		8,391				7,778				27,190				24,966
Operating income		3,801				3,341				11,685				10,383
OTHER INCOME (EXPENSE)
Interest expense		(45	)			(46	)			(145	)			(154	)
Interest income and other, net		253				215				711				589
INCOME BEFORE INCOME TAXES		4,009				3,510				12,251				10,818
Provision for income taxes		1,011				900				3,025				2,719
NET INCOME	$	2,998			$	2,610			$	9,226			$	8,099
NET INCOME PER COMMON SHARE:
Basic	$	6.75			$	5.88			$	20.78			$	18.24
Diluted	$	6.75			$	5.87			$	20.76			$	18.21
Shares used in calculation (000’s):
Basic		443,975				444,007				443,953				443,985
Diluted		444,364				444,706				444,427				444,803

COSTCO WHOLESALE CORPORATION CONSOLIDATED BALANCE SHEETS (amounts in millions, except par value and share data) (unaudited)
Subject to Reclassification
			August 30, 2026				August 31, 2025
ASSETS
CURRENT ASSETS
Cash and cash equivalents			$	20,207			$	14,161
Short-term investments				1,094				1,123
Receivables, net				3,959				3,203
Merchandise inventories				19,324				18,116
Other current assets				1,998				1,777
Total current assets				46,582				38,380
OTHER ASSETS
Property and equipment, net				35,633				31,909
Operating lease right-of-use assets				2,697				2,725
Other long-term assets				4,133				4,085
TOTAL ASSETS			$	89,045			$	77,099
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Accounts payable			$	22,591			$	19,783
Accrued salaries and benefits				5,641				5,205
Accrued member rewards				3,037				2,677
Deferred membership fees				3,006				2,854
Current portion of long-term debt				2,248				75
Other current liabilities				7,429				6,514
Total current liabilities				43,952				37,108
OTHER LIABILITIES
Long-term debt, excluding current portion				3,914				5,713
Long-term operating lease liabilities				2,414				2,460
Other long-term liabilities				2,962				2,654
TOTAL LIABILITIES				53,242				47,935
COMMITMENTS AND CONTINGENCIES
EQUITY
Preferred stock $0.005 par value; 100,000,000 shares authorized; no shares issued and outstanding				—				—
Common stock $0.005 par value; 900,000,000 shares authorized; 443,266,000 and 443,237,000 shares issued and outstanding				2				2
Additional paid-in capital				8,830				8,282
Accumulated other comprehensive loss				(1,620	)			(1,770	)
Retained earnings				28,591				22,650
TOTAL EQUITY				35,803				29,164
TOTAL LIABILITIES AND EQUITY			$	89,045			$	77,099

COSTCO WHOLESALE CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (amounts in millions) (unaudited)
Subject to Reclassification
	52 Weeks Ended
	August 30, 2026				August 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$	9,226			$	8,099
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		2,674				2,426
Non-cash lease expense		318				303
Stock-based compensation		924				860
Other non-cash operating activities, net		355				(117	)
Changes in working capital		2,328				1,764
Net cash provided by operating activities		15,825				13,335
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property and equipment		(6,435	)			(5,498	)
Purchases of short-term investments		(788	)			(1,028	)
Maturities of short-term investments		811				1,141
Other investing activities, net		26				74
Net cash used in investing activities		(6,386	)			(5,311	)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayments of short-term borrowings		(577	)			(862	)
Proceeds from short-term borrowings		553				816
Repayments of long-term debt		(69	)			(103	)
Proceeds from issuance of long-term debt		496				—
Tax withholdings on stock-based awards		(361	)			(393	)
Repurchases of common stock		(848	)			(903	)
Cash dividend payments		(2,458	)			(2,183	)
Financing lease payments and other financing activities, net		(91	)			(147	)
Net cash used in financing activities		(3,355	)			(3,775	)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		(38	)			6
Net change in cash and cash equivalents		6,046				4,255
CASH AND CASH EQUIVALENTS BEGINNING OF YEAR		14,161				9,906
CASH AND CASH EQUIVALENTS END OF YEAR	$	20,207			$	14,161

ISSAQUAH, Wash., Sept. 24, 2026 (GLOBE NEWSWIRE) — Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today announced its operating results for the 16-week fourth quarter and the 52-week fiscal year ended August 30, 2026.

Net sales for the quarter increased 11.2 percent, to $93.9 billion, from $84.4 billion last year. Net sales for the fiscal year increased 10.1 percent, to $297.2 billion, from $269.9 billion last year.

Comparable sales for the fourth quarter and fiscal year were as follows:

	16 Weeks		16 Weeks		52 Weeks		52 Weeks
			Adjusted*				Adjusted*
U.S.	10.7%		7.2%		8.2%		6.6%
Canada	5.0%		4.6%		7.8%		6.7%
Other International	7.0%		6.2%		9.8%		6.5%
Total Company	9.4%		6.7%		8.4%		6.6%
Digitally-Enabled	19.5%		19.8%		20.9%		20.7%

_{*Excluding the impacts from changes in gasoline prices and foreign exchange.}

Net income for the fourth quarter was $2.998 billion, $6.75 per diluted share, compared to $2.610 billion, $5.87 per diluted share, last year. This year’s fourth quarter was positively impacted by a non-recurring benefit of $0.15 per diluted share from IEEPA tariff refunds received in the quarter, less partial reinvestment of those refunds in increased member values. Net income for the fiscal year was $9.226 billion, $20.76 per diluted share, compared to $8.099 billion, $18.21 per diluted share, last year.

Costco currently operates 939 warehouses, including 647 in the United States and Puerto Rico, 115 in Canada, 43 in Mexico, 37 in Japan, 29 in the United Kingdom, 20 in Korea, 15 in Australia, 14 in Taiwan, seven in China, five in Spain, three in France, two in Sweden, and one each in Iceland, and New Zealand. Costco also operates e-commerce sites in the U.S., Canada, the U.K., Mexico, Korea, Taiwan, Japan, Australia, and China.

A conference call to discuss these results is scheduled for 2:00 p.m. (PT) today, September 24, 2026, and will be available via a webcast on investor.costco.com (click “Events & Presentations”).

Certain statements contained in this document constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For these purposes, forward-looking statements are statements that address activities, events, conditions or developments that the Company expects or anticipates may occur in the future. In some cases forward-looking statements can be identified because they contain words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms. Such forward-looking statements involve risks and uncertainties that may cause actual events, results or performance to differ materially from those indicated by such statements. These risks and uncertainties include, but are not limited to, domestic and international economic conditions, including exchange rates, inflation or deflation, the effects of competition and regulation, uncertainties in the financial markets, consumer and small business spending patterns and debt levels, breaches of security or privacy of member or business information, conditions affecting the acquisition, development, ownership or use of real estate, capital spending, actions of vendors, rising costs associated with employees (generally including health-care costs and wages), workforce interruptions, energy and certain commodities, geopolitical conditions (including tariffs and global conflicts), the ability to maintain effective internal control over financial reporting, regulatory and other impacts related to environmental and social matters, public-health related factors, and other risks identified from time to time in the Company’s public statements and reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company does not undertake to update these statements, except as required by law. Comparable sales and comparable sales excluding impacts from changes in gasoline prices and foreign exchange are intended as supplemental information and are not a substitute for net sales presented in accordance with U.S. GAAP.

CONTACTS:	Costco Wholesale Corporation
	Josh Dahmen, 425/313-8254
	Andrew Yoon, 425/313-6305
	Bryan Starnes, 425/427-7403

COST-Earn

COSTCO WHOLESALE CORPORATION CONSOLIDATED STATEMENTS OF INCOME (dollars in millions, except per share data) (unaudited)
	16 Weeks Ended								52 Weeks Ended
	August 30, 2026				August 31, 2025				August 30, 2026				August 31, 2025
REVENUE
Net sales	$	93,873			$	84,432			$	297,247			$	269,912
Membership fees		1,850				1,724				5,907				5,323
Total revenue		95,723				86,156				303,154				275,235
OPERATING EXPENSES
Merchandise costs		83,531				75,037				264,279				239,886
Selling, general and administrative		8,391				7,778				27,190				24,966
Operating income		3,801				3,341				11,685				10,383
OTHER INCOME (EXPENSE)
Interest expense		(45	)			(46	)			(145	)			(154	)
Interest income and other, net		253				215				711				589
INCOME BEFORE INCOME TAXES		4,009				3,510				12,251				10,818
Provision for income taxes		1,011				900				3,025				2,719
NET INCOME	$	2,998			$	2,610			$	9,226			$	8,099
NET INCOME PER COMMON SHARE:
Basic	$	6.75			$	5.88			$	20.78			$	18.24
Diluted	$	6.75			$	5.87			$	20.76			$	18.21
Shares used in calculation (000’s):
Basic		443,975				444,007				443,953				443,985
Diluted		444,364				444,706				444,427				444,803

COSTCO WHOLESALE CORPORATION CONSOLIDATED BALANCE SHEETS (amounts in millions, except par value and share data) (unaudited)
Subject to Reclassification
			August 30, 2026				August 31, 2025
ASSETS
CURRENT ASSETS
Cash and cash equivalents			$	20,207			$	14,161
Short-term investments				1,094				1,123
Receivables, net				3,959				3,203
Merchandise inventories				19,324				18,116
Other current assets				1,998				1,777
Total current assets				46,582				38,380
OTHER ASSETS
Property and equipment, net				35,633				31,909
Operating lease right-of-use assets				2,697				2,725
Other long-term assets				4,133				4,085
TOTAL ASSETS			$	89,045			$	77,099
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Accounts payable			$	22,591			$	19,783
Accrued salaries and benefits				5,641				5,205
Accrued member rewards				3,037				2,677
Deferred membership fees				3,006				2,854
Current portion of long-term debt				2,248				75
Other current liabilities				7,429				6,514
Total current liabilities				43,952				37,108
OTHER LIABILITIES
Long-term debt, excluding current portion				3,914				5,713
Long-term operating lease liabilities				2,414				2,460
Other long-term liabilities				2,962				2,654
TOTAL LIABILITIES				53,242				47,935
COMMITMENTS AND CONTINGENCIES
EQUITY
Preferred stock $0.005 par value; 100,000,000 shares authorized; no shares issued and outstanding				—				—
Common stock $0.005 par value; 900,000,000 shares authorized; 443,266,000 and 443,237,000 shares issued and outstanding				2				2
Additional paid-in capital				8,830				8,282
Accumulated other comprehensive loss				(1,620	)			(1,770	)
Retained earnings				28,591				22,650
TOTAL EQUITY				35,803				29,164
TOTAL LIABILITIES AND EQUITY			$	89,045			$	77,099

COSTCO WHOLESALE CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (amounts in millions) (unaudited)
Subject to Reclassification
	52 Weeks Ended
	August 30, 2026				August 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$	9,226			$	8,099
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		2,674				2,426
Non-cash lease expense		318				303
Stock-based compensation		924				860
Other non-cash operating activities, net		355				(117	)
Changes in working capital		2,328				1,764
Net cash provided by operating activities		15,825				13,335
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property and equipment		(6,435	)			(5,498	)
Purchases of short-term investments		(788	)			(1,028	)
Maturities of short-term investments		811				1,141
Other investing activities, net		26				74
Net cash used in investing activities		(6,386	)			(5,311	)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayments of short-term borrowings		(577	)			(862	)
Proceeds from short-term borrowings		553				816
Repayments of long-term debt		(69	)			(103	)
Proceeds from issuance of long-term debt		496				—
Tax withholdings on stock-based awards		(361	)			(393	)
Repurchases of common stock		(848	)			(903	)
Cash dividend payments		(2,458	)			(2,183	)
Financing lease payments and other financing activities, net		(91	)			(147	)
Net cash used in financing activities		(3,355	)			(3,775	)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		(38	)			6
Net change in cash and cash equivalents		6,046				4,255
CASH AND CASH EQUIVALENTS BEGINNING OF YEAR		14,161				9,906
CASH AND CASH EQUIVALENTS END OF YEAR	$	20,207			$	14,161

HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) — Big Sky Industrial Inc. (NASDAQ: BSIN) (“Big Sky Industrial” or the “Company”), an integrated industrial gas, energy, and carbon management company, today announced that its Chief Executive Officer, Ryan Smith, will participate in the Noble Capital Markets’ Emerging Growth Virtual Equity Conference on October 1.

During the event, Mr. Smith will present and host one-on-one meetings with investors. The presentation is currently scheduled to take place at 8:30 a.m. ET on October 1. The presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience.

Investors can view the live presentation at https://channelchek.cc/4yDOCxz or register for the event at no cost here.

To request a meeting with the Big Sky Industrial team, please reach out to Giorgia Pigato, from Noble Capital Markets, at gpigato@noblecapitalmarkets.com or the Company’s investor relations team at BSIN@elevate-ir.com.

A video webcast of the presentation will be available following the event on the Company’s website at www.bigskyindustrialinc.com. The webcast will be archived on the company’s website for 90 days following the event.

About Big Sky Industrial Inc.

Big Sky Industrial Inc. (NASDAQ: BSIN) is a Houston-based industrial gas, carbon management, and energy company with operations focused on the Big Sky Carbon Hub and Cut Bank oil field in Montana’s Kevin Dome region. The Company’s asset base supports three distinct business lines: helium production, carbon management, and low-decline oil production. Big Sky Industrial is focused on developing an integrated platform that leverages helium as a federally designated critical mineral, carbon management opportunities supported by Section 45Q federal tax credits, and conventional oil production from its owned and operated assets. The Company’s operations are designed to generate revenue from multiple independent sources across helium, carbon management, and oil. For more information, please visit www.bigskyindustrialinc.com.

INVESTOR RELATIONS CONTACT

Mason McGuire
IR@bigskyindustrialinc.com
(303) 993-3200
www.bigskyindustrialinc.com

HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) — Big Sky Industrial Inc. (NASDAQ: BSIN) (“Big Sky Industrial” or the “Company”), an integrated industrial gas, energy, and carbon management company, today announced that its Chief Executive Officer, Ryan Smith, will participate in the Noble Capital Markets’ Emerging Growth Virtual Equity Conference on October 1.

During the event, Mr. Smith will present and host one-on-one meetings with investors. The presentation is currently scheduled to take place at 8:30 a.m. ET on October 1. The presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience.

Investors can view the live presentation at https://channelchek.cc/4yDOCxz or register for the event at no cost here.

To request a meeting with the Big Sky Industrial team, please reach out to Giorgia Pigato, from Noble Capital Markets, at gpigato@noblecapitalmarkets.com or the Company’s investor relations team at BSIN@elevate-ir.com.

A video webcast of the presentation will be available following the event on the Company’s website at www.bigskyindustrialinc.com. The webcast will be archived on the company’s website for 90 days following the event.

About Big Sky Industrial Inc.

Big Sky Industrial Inc. (NASDAQ: BSIN) is a Houston-based industrial gas, carbon management, and energy company with operations focused on the Big Sky Carbon Hub and Cut Bank oil field in Montana’s Kevin Dome region. The Company’s asset base supports three distinct business lines: helium production, carbon management, and low-decline oil production. Big Sky Industrial is focused on developing an integrated platform that leverages helium as a federally designated critical mineral, carbon management opportunities supported by Section 45Q federal tax credits, and conventional oil production from its owned and operated assets. The Company’s operations are designed to generate revenue from multiple independent sources across helium, carbon management, and oil. For more information, please visit www.bigskyindustrialinc.com.

INVESTOR RELATIONS CONTACT

Mason McGuire
IR@bigskyindustrialinc.com
(303) 993-3200
www.bigskyindustrialinc.com

Client feedback moves Hudson Talent Solutions up to No. 3 ranking in 2026

Top-five rankings in Quality of Service, Breadth of Service, and Size of Deals

OLD GREENWICH, Conn., Sept. 24, 2026 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star” or the “Company”), a diversified holding company, announced today that its wholly owned subsidiary, Hudson Talent Solutions (“HTS”) operating inside the Business Services division, has been named one of the world’s leading recruitment process outsourcing (“RPO”) providers in HRO Today’s 2026 Global RPO Baker’s Dozen Customer Satisfaction Ratings.

This is the 18^th consecutive year HTS has been named to the Global RPO Baker’s Dozen. In the 2026 ratings, HTS ranked No. 3 overall globally, up from No. 5 in 2025. HTS also ranked No. 3 for Quality of Service, No. 4 for Breadth of Service, and No. 5 for Size of Deals.

The HRO Today Baker’s Dozen rankings are based exclusively on client feedback. RPO providers are assessed on the breadth of their services, the scale and scope of the programs they support, and the quality of the client experience.

This recognition reinforces HTS’s strong market position, long-standing client relationships, global delivery capabilities, and ongoing investment in technology-enabled talent acquisition solutions. HTS continues to evolve its RPO model by combining global delivery expertise, talent advisory services, and agentic AI technology across the talent acquisition lifecycle. Its solutions help organizations improve hiring outcomes, adapt more quickly to changing workforce needs, and build scalable, high-performing recruitment functions.

“HRO Today’s recognition of HTS is particularly meaningful because it is based on feedback from RPO clients,” said Jeff Eberwein, CEO of Star Equity. “Our move to No. 3 globally, alongside 18 consecutive years of recognition, reflects the strength of HTS’s client relationships, global delivery platform, and management team. We believe HTS’s ability to combine talent advisory, scalable service delivery, and technology, including agentic AI, enables our team to meet the increasingly complex hiring needs of large organizations.”

“This recognition means so much because it comes directly from our clients,” said Jake Zabkowicz, Global CEO of Hudson Talent Solutions. “Their trust, partnership, and honest feedback shape how we continue to evolve. To be recognized for 18 consecutive years reflects the consistency of our teams around the world, and our commitment to helping clients solve increasingly complex talent challenges.”

“Over the past year, we have continued to invest in our people, technology, and delivery capabilities, always with a clear focus on helping our clients achieve better results,” Mr. Zabkowicz added. “I’m proud of the work our teams are doing and grateful to our clients for their trust and partnership.”

Continued Industry Recognition
HTS’ placement in the 2026 Baker’s Dozen builds on broader industry recognition of the company’s global capabilities, including:

• Recognition as a Major Contender and Star Performer in Everest Group’s Global Recruitment Process Outsourcing PEAK Matrix^® Assessment
• Recognition as a Major Contender across all regions and a Star Performer in EMEA and APAC in Everest Group’s Regional RPO PEAK Matrix^® Assessments
• Classification as a Leader across every evaluated category in NelsonHall’s NEAT assessment of RPO providers
• No. 1 placement in HRO Today’s 2023, 2024, and 2025 APAC RPO Baker’s Dozen Customer Satisfaction Ratings

About Hudson Talent Solutions
Hudson Talent Solutions is a global talent advisory and solutions partner helping organizations build stronger, more agile workforces. Hudson brings together strategic advisory, recruitment expertise, global delivery, and AI-enabled technology to help clients solve complex hiring challenges and improve talent outcomes. From Recruitment Process Outsourcing and project-based recruitment to talent consulting, sourcing, and executive search, Hudson delivers flexible solutions tailored to the needs of mid-market and enterprise organizations worldwide. Learn more at hudsontalent.com.

About Star Equity Holdings, Inc.
Star Equity Holdings, Inc. is a diversified holding company that seeks to build long-term shareholder value by acquiring, managing, and growing businesses with strong fundamentals and market opportunities. Its current structure comprises four divisions: Building Solutions, Business Services, Energy Services, and Investments. For more information visit www.starequity.com.

Building Solutions
The Building Solutions division operates in three specialties: (i) modular building manufacturing; (ii) structural wall panel and wood foundation manufacturing, including building supply distribution operations; and (iii) glue-laminated timber (glulam) column, beam, and truss manufacturing.

Business Services
The Business Services division provides flexible and scalable recruitment solutions to a global clientele, servicing organizations at all levels, from entry-level positions to the C-suite. The division focuses on mid-market and enterprise organizations worldwide, partnering consultatively with talent acquisition, HR, and procurement leaders to build diverse, high-impact teams and drive business success.

Energy Services
The Energy Services division engages in the rental, sale, and repair of downhole tools used in the oil and gas, geothermal, mining, and water-well industries.

Investments
The Investments division manages and finances the Company’s real estate assets as well as its investment positions in private and public companies.

Forward-Looking Statements
This press release contains statements that the Company believes to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe,” and similar words, expressions, and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties, and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Such factors, risks, uncertainties, and assumptions include, but are not limited to, (1) global economic fluctuations, (2) changes in the cost and availability of commodities, materials, and equipment, (3) risks related to providing uninterrupted service to clients, (4) the ability of clients to terminate their relationship with the Company at any time, (5) risks associated with real estate ownership, (6) the Company’s ability to successfully achieve its strategic initiatives, (7) risks related to fluctuations in the Company’s operating results from quarter to quarter, (8) risks related to potential acquisitions or dispositions of businesses by the Company, (9) our profitability and growth being tied to the success of our operating businesses, (10) risks associated with our financial investments in other businesses, (11) our ability to improve existing products and services and develop, introduce, and market new products and services successfully, (12) the loss of or material reduction in our business with any of the Company’s largest customers, (13) competition in the Company’s markets, (14) risks related to potential decreases in demand for products, (15) our ability to maintain costs at an acceptable level, (16) the negative cash flows and operating losses that may recur in the future, (17) risks related to international operations, including foreign currency fluctuations, political events, trade wars, natural disasters or health crises, including the Russia-Ukraine war, and potential conflict in the Middle East, (18) risks relating to how future credit facilities may affect or restrict our operating flexibility, (19) our ability to generate or borrow sufficient cash to make payments on our indebtedness, (20) risks related to indebtedness, (21) risks associated with the Company’s investment strategy, (22) the Company’s dependence on key management personnel, (23) the Company’s ability to attract and retain highly skilled professionals, management, and advisors, (24) the Company’s ability to collect accounts receivable, (25) the Company’s exposure to legal proceedings, investigations and disputes, and limits on related insurance coverage, (26) the Company’s ability to utilize net operating loss carryforwards, (27) the potential for goodwill impairment, (28) volatility of the Company’s stock price, (29) risks related to our historically low trading volume, (30) risks related to securities or industry analysts, (31) the Company’s ability to declare dividends, (32) risks associated with failure to pay dividends on our Series A Preferred Stock, (33) our history of annual net losses, (34) risks related to our international operations, (35) risks related to compliance with federal and state laws, regulations, and other rules, (36) our exposure to employment-related claims, legal liability, and costs from clients, employees, and regulatory authorities, (37) risks related to the imposition of licensing or tax requirements or new regulations, (38) the effect of Anti-takeover provisions in our organizational documents, (39) the effect of the protective amendment contained in our Restated Certificate of Incorporation, (40) the impact of our stockholder rights plan, or “poison pill,” on stockholder decision making, (41) risks related to our scaled disclosure requirements as a smaller reporting company, (42) the Company’s heavy reliance on information systems and the impact of potentially losing or failing to develop technology, (43) the adverse impacts of cybersecurity threats and attacks, and (44) risks related to the use of new and evolving technologies, and (45) those risks set forth in “Risk Factors in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.” The foregoing list should not be construed to be exhaustive. Actual results could differ materially from the forward-looking statements contained in this press release. In view of these uncertainties, you should not place undue reliance on any forward-looking statements, which are based on our current expectations. These forward-looking statements speak only as of the date of this press release. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information contact:
The Equity Group
Lena Cati
Senior Vice President
212-836-9611
lcati@theequitygroup.com

Client feedback moves Hudson Talent Solutions up to No. 3 ranking in 2026

Top-five rankings in Quality of Service, Breadth of Service, and Size of Deals

OLD GREENWICH, Conn., Sept. 24, 2026 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star” or the “Company”), a diversified holding company, announced today that its wholly owned subsidiary, Hudson Talent Solutions (“HTS”) operating inside the Business Services division, has been named one of the world’s leading recruitment process outsourcing (“RPO”) providers in HRO Today’s 2026 Global RPO Baker’s Dozen Customer Satisfaction Ratings.

This is the 18^th consecutive year HTS has been named to the Global RPO Baker’s Dozen. In the 2026 ratings, HTS ranked No. 3 overall globally, up from No. 5 in 2025. HTS also ranked No. 3 for Quality of Service, No. 4 for Breadth of Service, and No. 5 for Size of Deals.

The HRO Today Baker’s Dozen rankings are based exclusively on client feedback. RPO providers are assessed on the breadth of their services, the scale and scope of the programs they support, and the quality of the client experience.

This recognition reinforces HTS’s strong market position, long-standing client relationships, global delivery capabilities, and ongoing investment in technology-enabled talent acquisition solutions. HTS continues to evolve its RPO model by combining global delivery expertise, talent advisory services, and agentic AI technology across the talent acquisition lifecycle. Its solutions help organizations improve hiring outcomes, adapt more quickly to changing workforce needs, and build scalable, high-performing recruitment functions.

“HRO Today’s recognition of HTS is particularly meaningful because it is based on feedback from RPO clients,” said Jeff Eberwein, CEO of Star Equity. “Our move to No. 3 globally, alongside 18 consecutive years of recognition, reflects the strength of HTS’s client relationships, global delivery platform, and management team. We believe HTS’s ability to combine talent advisory, scalable service delivery, and technology, including agentic AI, enables our team to meet the increasingly complex hiring needs of large organizations.”

“This recognition means so much because it comes directly from our clients,” said Jake Zabkowicz, Global CEO of Hudson Talent Solutions. “Their trust, partnership, and honest feedback shape how we continue to evolve. To be recognized for 18 consecutive years reflects the consistency of our teams around the world, and our commitment to helping clients solve increasingly complex talent challenges.”

“Over the past year, we have continued to invest in our people, technology, and delivery capabilities, always with a clear focus on helping our clients achieve better results,” Mr. Zabkowicz added. “I’m proud of the work our teams are doing and grateful to our clients for their trust and partnership.”

Continued Industry Recognition
HTS’ placement in the 2026 Baker’s Dozen builds on broader industry recognition of the company’s global capabilities, including:

• Recognition as a Major Contender and Star Performer in Everest Group’s Global Recruitment Process Outsourcing PEAK Matrix^® Assessment
• Recognition as a Major Contender across all regions and a Star Performer in EMEA and APAC in Everest Group’s Regional RPO PEAK Matrix^® Assessments
• Classification as a Leader across every evaluated category in NelsonHall’s NEAT assessment of RPO providers
• No. 1 placement in HRO Today’s 2023, 2024, and 2025 APAC RPO Baker’s Dozen Customer Satisfaction Ratings

About Hudson Talent Solutions
Hudson Talent Solutions is a global talent advisory and solutions partner helping organizations build stronger, more agile workforces. Hudson brings together strategic advisory, recruitment expertise, global delivery, and AI-enabled technology to help clients solve complex hiring challenges and improve talent outcomes. From Recruitment Process Outsourcing and project-based recruitment to talent consulting, sourcing, and executive search, Hudson delivers flexible solutions tailored to the needs of mid-market and enterprise organizations worldwide. Learn more at hudsontalent.com.

About Star Equity Holdings, Inc.
Star Equity Holdings, Inc. is a diversified holding company that seeks to build long-term shareholder value by acquiring, managing, and growing businesses with strong fundamentals and market opportunities. Its current structure comprises four divisions: Building Solutions, Business Services, Energy Services, and Investments. For more information visit www.starequity.com.

Building Solutions
The Building Solutions division operates in three specialties: (i) modular building manufacturing; (ii) structural wall panel and wood foundation manufacturing, including building supply distribution operations; and (iii) glue-laminated timber (glulam) column, beam, and truss manufacturing.

Business Services
The Business Services division provides flexible and scalable recruitment solutions to a global clientele, servicing organizations at all levels, from entry-level positions to the C-suite. The division focuses on mid-market and enterprise organizations worldwide, partnering consultatively with talent acquisition, HR, and procurement leaders to build diverse, high-impact teams and drive business success.

Energy Services
The Energy Services division engages in the rental, sale, and repair of downhole tools used in the oil and gas, geothermal, mining, and water-well industries.

Investments
The Investments division manages and finances the Company’s real estate assets as well as its investment positions in private and public companies.

Forward-Looking Statements
This press release contains statements that the Company believes to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe,” and similar words, expressions, and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties, and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Such factors, risks, uncertainties, and assumptions include, but are not limited to, (1) global economic fluctuations, (2) changes in the cost and availability of commodities, materials, and equipment, (3) risks related to providing uninterrupted service to clients, (4) the ability of clients to terminate their relationship with the Company at any time, (5) risks associated with real estate ownership, (6) the Company’s ability to successfully achieve its strategic initiatives, (7) risks related to fluctuations in the Company’s operating results from quarter to quarter, (8) risks related to potential acquisitions or dispositions of businesses by the Company, (9) our profitability and growth being tied to the success of our operating businesses, (10) risks associated with our financial investments in other businesses, (11) our ability to improve existing products and services and develop, introduce, and market new products and services successfully, (12) the loss of or material reduction in our business with any of the Company’s largest customers, (13) competition in the Company’s markets, (14) risks related to potential decreases in demand for products, (15) our ability to maintain costs at an acceptable level, (16) the negative cash flows and operating losses that may recur in the future, (17) risks related to international operations, including foreign currency fluctuations, political events, trade wars, natural disasters or health crises, including the Russia-Ukraine war, and potential conflict in the Middle East, (18) risks relating to how future credit facilities may affect or restrict our operating flexibility, (19) our ability to generate or borrow sufficient cash to make payments on our indebtedness, (20) risks related to indebtedness, (21) risks associated with the Company’s investment strategy, (22) the Company’s dependence on key management personnel, (23) the Company’s ability to attract and retain highly skilled professionals, management, and advisors, (24) the Company’s ability to collect accounts receivable, (25) the Company’s exposure to legal proceedings, investigations and disputes, and limits on related insurance coverage, (26) the Company’s ability to utilize net operating loss carryforwards, (27) the potential for goodwill impairment, (28) volatility of the Company’s stock price, (29) risks related to our historically low trading volume, (30) risks related to securities or industry analysts, (31) the Company’s ability to declare dividends, (32) risks associated with failure to pay dividends on our Series A Preferred Stock, (33) our history of annual net losses, (34) risks related to our international operations, (35) risks related to compliance with federal and state laws, regulations, and other rules, (36) our exposure to employment-related claims, legal liability, and costs from clients, employees, and regulatory authorities, (37) risks related to the imposition of licensing or tax requirements or new regulations, (38) the effect of Anti-takeover provisions in our organizational documents, (39) the effect of the protective amendment contained in our Restated Certificate of Incorporation, (40) the impact of our stockholder rights plan, or “poison pill,” on stockholder decision making, (41) risks related to our scaled disclosure requirements as a smaller reporting company, (42) the Company’s heavy reliance on information systems and the impact of potentially losing or failing to develop technology, (43) the adverse impacts of cybersecurity threats and attacks, and (44) risks related to the use of new and evolving technologies, and (45) those risks set forth in “Risk Factors in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.” The foregoing list should not be construed to be exhaustive. Actual results could differ materially from the forward-looking statements contained in this press release. In view of these uncertainties, you should not place undue reliance on any forward-looking statements, which are based on our current expectations. These forward-looking statements speak only as of the date of this press release. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information contact:
The Equity Group
Lena Cati
Senior Vice President
212-836-9611
lcati@theequitygroup.com

Ticker symbols to change from FGNX and FGNXP to FGC and FGCPP on Nasdaq

Charlotte, NC, Sept. 24, 2026 (GLOBE NEWSWIRE) — FG Nexus (Nasdaq: FGNX, FGNXP) (the “Company”) announced that it has filed a Certificate of Amendment to its amended and restated articles of incorporation with the Nevada Secretary of State. Pursuant to the Certificate of Amendment, the Company will change its name to FG Communities Holdings Inc. In conjunction with the name change, the Company’s ticker symbols on The Nasdaq Stock Market will change as follows to: FGC for its Common Stock replacing the previous symbol “FGNX” and FGCPP for its Series A Preferred Shares, replacing the previous symbol “FGNXP,” effective at market open on Monday, September 28, 2026.

Kyle Cerminara, Chairman and CEO, commented, “We have made tremendous progress evolving our business model, and the new name better reflects our transformation into a leading owner and operator of land-lease affordable housing communities. We look forward to driving sustained long-term value for our shareholders.”

About FG Nexus Inc.

FG Nexus (Nasdaq: FGNX, FGNXP) is a merchant bank and real estate focused operating company.

The FGNX^® logo is a registered trademark.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are entitled to the protection of the safe-harbor provisions of those laws.

Forward-looking statements include statements concerning the closing and anticipated benefits of the Company’s proposed investment in FG Communities; the Company’s strategy to make direct investments in affordable housing communities; the acquisition, ownership, operation and financing of manufactured housing communities; the use of cash, debt financing and proceeds from common-stock issuances to fund acquisitions; the proposed corporate name and ticker-symbol changes; future share repurchases; the Company’s acquisition pipeline and growth strategy; and the anticipated size and long-term characteristics of the manufactured housing market.

These statements are based on management’s current expectations, assumptions, estimates and projections and involve risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from those expressed or implied by these statements.

Relevant risks include, among others, the Company’s ability to complete the proposed investment on anticipated terms; obtain required corporate, regulatory and Nasdaq approvals; successfully identify, finance, complete and integrate property acquisitions; obtain debt or equity financing on acceptable terms; manage leverage and potential dilution from equity issuances; realize anticipated operating and financial benefits; maintain adequate liquidity; and appropriately manage potential conflicts of interest arising from related-party transactions.

Additional risks are described in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statement except as required by law.

Contacts

Media Contact
media@fgnexus.io

Investor Contact
invest@fgnexus.io

Ticker symbols to change from FGNX and FGNXP to FGC and FGCPP on Nasdaq

Charlotte, NC, Sept. 24, 2026 (GLOBE NEWSWIRE) — FG Nexus (Nasdaq: FGNX, FGNXP) (the “Company”) announced that it has filed a Certificate of Amendment to its amended and restated articles of incorporation with the Nevada Secretary of State. Pursuant to the Certificate of Amendment, the Company will change its name to FG Communities Holdings Inc. In conjunction with the name change, the Company’s ticker symbols on The Nasdaq Stock Market will change as follows to: FGC for its Common Stock replacing the previous symbol “FGNX” and FGCPP for its Series A Preferred Shares, replacing the previous symbol “FGNXP,” effective at market open on Monday, September 28, 2026.

Kyle Cerminara, Chairman and CEO, commented, “We have made tremendous progress evolving our business model, and the new name better reflects our transformation into a leading owner and operator of land-lease affordable housing communities. We look forward to driving sustained long-term value for our shareholders.”

About FG Nexus Inc.

FG Nexus (Nasdaq: FGNX, FGNXP) is a merchant bank and real estate focused operating company.

The FGNX^® logo is a registered trademark.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are entitled to the protection of the safe-harbor provisions of those laws.

Forward-looking statements include statements concerning the closing and anticipated benefits of the Company’s proposed investment in FG Communities; the Company’s strategy to make direct investments in affordable housing communities; the acquisition, ownership, operation and financing of manufactured housing communities; the use of cash, debt financing and proceeds from common-stock issuances to fund acquisitions; the proposed corporate name and ticker-symbol changes; future share repurchases; the Company’s acquisition pipeline and growth strategy; and the anticipated size and long-term characteristics of the manufactured housing market.

These statements are based on management’s current expectations, assumptions, estimates and projections and involve risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from those expressed or implied by these statements.

Relevant risks include, among others, the Company’s ability to complete the proposed investment on anticipated terms; obtain required corporate, regulatory and Nasdaq approvals; successfully identify, finance, complete and integrate property acquisitions; obtain debt or equity financing on acceptable terms; manage leverage and potential dilution from equity issuances; realize anticipated operating and financial benefits; maintain adequate liquidity; and appropriately manage potential conflicts of interest arising from related-party transactions.

Additional risks are described in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statement except as required by law.

Contacts

Media Contact
media@fgnexus.io

Investor Contact
invest@fgnexus.io